Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer

NCT01300533 is registered in ClinicalTrials.gov with BIND Therapeutics as lead sponsor.

NCT NCT01300533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01300533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Lead sponsor
BIND Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2011
Completion date
February 29, 2016
Enrollment
58 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, metastatic cancer, solid tumors